1314 ET - Hims & Hers' launch of generic liraglutide is likely to contribute more to the telehealth platform's growth than offering Eli Lilly's Zepbound, Leerink Partners analyst Michael Cherny tells WSJ. The liraglutide launch comes a month earlier than expected and could help boost quarterly revenue, as the company is looking for alternatives to its compounded semaglutide drug, which the FDA is cracking down on now that shortages of GLP-1s are over. Liraglutide falls more in line with Hims business model of offering affordable treatments, Cherney says, as it would cost around $299 a month vs. $1,899 a month for Zepbound.(katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 13:14 ET (17:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.